surmount-1 tirzepatide weight loss percent nejm 2022 For the first time, and semaglutide were put in the same trial. SURMOUNT-5. Phase 3b RCT. 751 adults with obesity, no diabetes. 72 weeks. Both drugs at maximum tolerated dose. The 📊 Semaglutide 2.4mg: −13.7% weight

Bruijn N, van Lohuizen R, Boron M, Fitzek M, Gabriele F, Giuliani G et al (2024) Influence of metabolic state and body composition on the action of pharmacological treatment of migraine

Phase 3 trials for obesity completed in August 2025

GLP-1 medications like Wegovy and Zepbound have rapidly reshaped metabolic care, expanding from Type 2 diabetes treatment to widely used weight management tools when combined with diet and exercise

At the same time, our preclinical safety evaluation studies showed that BPC157 was well tolerated and did not demonstrate any serious toxic effects in mice, rats, rabbits, or dogs (Xu et al., 2020)